Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSPO | P30536 | 2/20 | 0.41 |
| ▸ | PER2 | O15055 | 1/20 | 0.39 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.39 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL416453 | 0.84 | TSPO (0.55) | TSPO | |
| SCHEMBL875941 | 0.75 | TSPO (0.40) | TSPOPER2CRY1CRY2 | |
| SCHEMBL875520 | 0.75 | TSPO (0.40) | TSPOPER2CRY1CRY2 | |
| SCHEMBL876132 | 0.73 | TSPO (0.43) | TSPO | |
| SCHEMBL875781 | 0.73 | TSPO (0.45) | TSPO | |
| SCHEMBL875537 | 0.72 | TSPO (0.54) | TSPO | |
| SCHEMBL416794 | 0.72 | TSPO (0.56) | TSPO | |
| SCHEMBL414227 | 0.71 | TSPO (0.61) | TSPO | |
| SCHEMBL15101782 | 0.71 | TSPO (0.70) | TSPO | |
| SCHEMBL415392 | 0.71 | TSPO (0.70) | TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2618850-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | GE Healthcare UK Limited (GB) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038532-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | GE HEALTHCARE LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |